Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.81 Average PT from Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been given a consensus rating of “Hold” by the nineteen ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.81.

Several equities research analysts have recently commented on SAGE shares. Stifel Nicolaus reduced their price target on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research report on Monday, December 16th. Canaccord Genuity Group reduced their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, February 12th. Scotiabank dropped their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, February 12th. Wedbush restated a “neutral” rating and issued a $6.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th.

Sage Therapeutics Trading Down 4.4 %

NASDAQ:SAGE opened at $8.28 on Friday. The company has a 50 day simple moving average of $7.48 and a two-hundred day simple moving average of $6.73. The company has a market cap of $509.06 million, a PE ratio of -1.26 and a beta of 0.82. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $18.76.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Research analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SAGE. State Street Corp boosted its position in shares of Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares during the last quarter. RTW Investments LP boosted its holdings in shares of Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after purchasing an additional 111,123 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Sage Therapeutics by 10.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after purchasing an additional 43,617 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Sage Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after purchasing an additional 3,757 shares during the last quarter. Finally, Amundi purchased a new stake in shares of Sage Therapeutics in the fourth quarter worth about $166,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.